Dermatology
Conference Coverage
Topical ruxolitinib quickly relieves atopic dermatitis itch in Black patients
Ruxolitinib cream provides quick itch relief for Black patients with atopic dermatitis, researchers report.
Latest News
COVID skin manifestations vary by type of variant, U.K. study finds
Omicron and Delta COVID-19 skin manifestations differ, according to large U.K. patient survey.
Latest News
Devices to detect skin cancer: FDA advisers offer mixed views
There's been a swell in recent years in the number of publications related to the use of AI and machine learning, which could give rise to new...
Latest News
Skin-picking, hair-pulling disorders: Diagnostic criteria, prevalence, and treatment
Affected children “have type A personalities,” and are “very driven young kids,” Dr. Jon E. Grant said.
Latest News
Banana Boat recalls scalp sunscreen spray
The recall comes a little over a year after Johnson & Johnson recalled five sunscreens due to low levels of benzene.
Latest News
Topical roflumilast approved for psoriasis in adults and adolescents
In clinical trials, topical roflumilast was effective in treating psoriasis in intertriginous areas, including the buttocks, underarms, and...
Latest News
FDA panel urges caution with skin cancer–detecting tools
The FDA called a meeting amid growing interest in using technology to aid in finding cancers, with some of these products already marketed to...
Latest News
To gauge monkeypox spread, researchers eye cases in women
Researchers have recently published guidance on monkeypox for ob.gyns., maternal-fetal medicine subspecialists, and people who are pregnant or...
Latest News
Questionnaire for patients with psoriasis might identify risk of axial involvement
A patient-completed questionnaire shows promise for detecting risk of undiagnosed axial involvement in psoriasis.
Latest News
NAFLD strongly correlated with psoriasis, PsA; risk linked to severity
The risk of nonalcoholic fatty liver disease is doubled by psoriasis, and severity is a related variable.
Latest News
FDA approves topical ruxolitinib for nonsegmental vitiligo
Approval was based on the results of two phase 3 trials in 674 patients with nonsegmental vitiligo aged 12 years or older.